

## **Global Irritable Bowel Syndrome and Inflammatory Bowel Disease Therapeutics Market**

Market Research Report | 2025-07-10 | 155 pages | BCC Research

### **AVAILABLE LICENSES:**

- Single User License \$4650.00
- 2-5 Users License \$5580.00
- Site License \$6696.00
- Enterprise License \$8035.00

### **Report description:**

Description

#### Report Scope

The report provides an overview of the global irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) therapeutics market and analyzes market trends. It includes global revenue (\$ million) for the base year 2024, estimated data for 2025 and forecast data from 2026 through 2030. The market is segmented into irritable bowel syndrome and inflammatory bowel disease based on disease type. The IBS therapeutics segment is further segmented based on symptom type and drug class.

- By symptom type, IBS therapeutics include IBS with constipation (IBS-C), IBS with diarrhea (IBS-D) and IBS with mixed symptoms (IBS-M).
  - By drug class, IBS therapeutics include guanylate cyclase-C agonists, antibiotics, laxatives, antispasmodics and others.
- The IBD therapeutics segment is further segmented based on type and drug class.
- By type, IBD therapeutics include ulcerative colitis and Crohn's disease.
  - By drug class, therapeutics for IBD include interleukin inhibitors, integrin antagonists, TNF inhibitors, JAK (Janus kinases) inhibitors, and others

The report also focuses on regional market segmentation. The regions covered in this study include North America, Europe, Asia-Pacific, South America and the Middle East and Africa (MEA), focusing on significant countries in these regions. The report includes an analysis of the competitive landscape, which provides the ranking and share of key businesses in the global IBS and IBD therapeutics market. A dedicated section of company profiles providing details about leading market enterprises is also included.

The scope does not cover alternative therapies for IBS and IBD, such as herbal medicine, dietary supplements and behavioral therapies.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scott-international.com](mailto:support@scott-international.com)

[www.scott-international.com](http://www.scott-international.com)

## Report Includes

- 142 data tables and 54 additional tables
- Analysis of the global market for irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) therapeutics
- Analyses of global market trends, with historic revenue data from 2022 to 2024, estimates for 2025, and projected CAGRs through 2030
- Estimates of the market's size and revenue prospects, along with a corresponding market share analysis by symptom type, drug class, type, and region
- Facts and figures pertaining to market dynamics, technological advances, regulations and the impact of macroeconomic factors
- Insights derived from Porter's Five Forces model, as well as global supply chain analysis
- Patent analysis, featuring key granted and published patents
- Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, as well as the ESG risk ratings and practices of leading companies
- Analysis of the industry structure, including companies' market shares and rankings, strategic alliances, M&A activity and a venture funding outlook
- Profiles of the leading companies, including AbbVie Inc., Johnson & Johnson Services Inc., Ironwood Pharmaceuticals, Takeda Pharmaceuticals, and Amgen Inc.

## Executive Summary

### Summary:

The global market for irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) therapeutics is expected to grow from \$33.3 billion in 2025 and is projected to reach \$52.6 billion by the end of 2030, at a compound annual growth rate (CAGR) of 9.6% during the forecast period of 2025 to 2030.

IBS and IBD are types of gastrointestinal diseases. The pathophysiology of both diseases is unknown and is believed to be influenced by environmental factors, ethnicity, dietary habits and genetic predisposition. Due to varied symptoms, patients must use multiple therapeutics simultaneously. Therapeutics aim to improve patients' quality of life and achieve clinical remission for the longest period possible.

The key businesses in the IBS therapeutics market include Ironwood Pharmaceuticals, AstraZeneca, AbbVie, Abbott and Allergan. In the IBD therapeutics market, corporations include AbbVie, Johnson & Johnson Services Inc., Amgen and Biogen. Start-up companies are increasingly entering the IBS and IBD therapeutics market with novel pipeline candidates. Global pharmaceutical companies, such as AbbVie and Amgen, are focused on label expansion studies and licensing collaborations with small businesses to develop and market products.

### **Table of Contents:**

Table of Contents
Chapter 1 Executive Summary
Market Outlook
Scope of Report
Market Summary
Emerging Technologies
Segmental Analysis
Regional Analysis
Conclusion
Chapter 2 Market Overview

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

Overview  
Inflammatory Bowel Disease  
Irritable Bowel Syndrome  
Porter's Five Forces Analysis in the IBS and IBD Therapeutics Market  
Potential of New Entrants (Low to Moderate)  
Bargaining Power of Suppliers (Low)  
Bargaining Power of Buyers (High)  
Threat of Substitute Products (Moderate)  
Industry Rivalry (High)  
Impact of U.S. Tariffs  
Macroeconomic Factor Analysis  
Population Demographics and Aging Populations  
Government Policies on Drug Prices  
Chapter 3 Market Dynamics  
Market Dynamics  
Market Drivers  
Rising Prevalence of Gastrointestinal Disorders  
Increasing Entry of Biologics and Biosimilars  
Market Restraints  
Side Effects and Ceiling Impact of Biologics  
Overlap with Other GI Disorders  
Use of Alternative Treatment Approaches  
Market Opportunities  
Self-Administered Drugs  
Personalized Therapies  
Chapter 4 Regulatory Landscape  
Regulatory Aspects of IBS and IBD Therapeutics  
The U.S.  
European Union  
Asia-Pacific  
Chapter 5 Emerging Technologies and Pipeline Analysis  
Key Takeaways  
Emerging Technologies  
Novel Target-Based Small-Molecule Drugs  
Microbiome-Based Therapeutics  
Advanced Combination Treatments  
AI for Drug Discovery  
Pipeline Analysis  
Chapter 6 Market Segmentation Analysis  
Segmentation Breakdown  
Market Analysis by Disease  
Key Takeaways  
Irritable Bowel Syndrome  
Inflammatory Bowel Disease  
Market Analysis by Drug Class  
Key Takeaways  
Irritable Bowel Syndrome

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

Inflammatory Bowel Disease  
Geographic Breakdown  
Market Analysis by Region  
Key Takeaways  
North America  
Europe  
Asia-Pacific  
South America  
Middle East and Africa  
Chapter 7 Competitive Intelligence  
Key Takeaways  
Industry Structure  
Company Share Analysis of the IBD Therapeutics Market  
Competitive Share Analysis of the IBS Therapeutics Market  
Strategic Analysis  
Chapter 8 Sustainability in the IBS and IBD Market: An ESG Perspective  
Introduction to ESG  
ESG Risk Ratings  
Conclusion  
Chapter 9 Appendix  
Methodology  
Sources  
Abbreviations  
Company Profiles  
ABBVIE INC.  
AMGEN INC.  
ASTRAZENECA  
BAYER AG  
BIOGEN  
BRISTOL-MYERS SQUIBB CO.  
GILEAD SCIENCES INC.  
IRONWOOD  
JOHNSON & JOHNSON SERVICES INC.  
LILLY  
MERCK & CO. INC.  
PFIZER INC.  
SANOFI  
TAKEDA PHARMACEUTICAL CO. LTD.  
UCB S.A.  
Emerging Start-ups/ Market Disruptors

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

**Global Irritable Bowel Syndrome and Inflammatory Bowel Disease Therapeutics  
Market**

Market Research Report | 2025-07-10 | 155 pages | BCC Research

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

**ORDER FORM:**

Select license	License	Price
	Single User License	\$4650.00
	2-5 Users License	\$5580.00
	Site License	\$6696.00
	Enterprise License	\$8035.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-06-09"/>
		Signature	

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com



**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

[www.scotts-international.com](http://www.scotts-international.com)